244219-73-6

Basic information

• Product Name: (1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid benzyl ester
• Synonyms: (1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid benzyl ester
• CAS NO: 244219-73-6
• Molecular Weight: 320.435
• Mol File: 244219-73-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid benzyl ester(244219-73-6)
• EPA Substance Registry System: (1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid benzyl ester(244219-73-6)

Safety Data

• Hazardous Substances Data: 244219-73-6(Hazardous Substances Data)

Upstream product

• 294-90-6 1,4,7,10-tetraazacyclododecan 
• 5437-45-6 Benzyl bromoacetate 

Downstream Products

• 857677-10-2 octahydro-7H,9bH-2a,4a,7,9a-tetraazacycloocta[cd]pentalene-7-acetic acid phenylmethyl ester 
• 906064-66-2 1,4,7,10-tetraazacyclododecane-4,7,10-tricarboxymethyl methylester-1-carboxymethyl-benzylester 
• 137076-54-1 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 
• 192635-89-5 phenylmethyl 2-(1,4,7,10-Tetraaza-4,7,10-tris(((tert-butyl)oxycarbonyl)methyl)cyclododecyl)-acetate 

Relevant articles and documents

Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds

DOTA (1,4,7,10-tetraazacyclodocecane-N,N′,N″,N?-tetraacetic acid), which forms extremely stable complexes with a large number of metal ions, is one of the most important and most commonly used chelators for in vivo applications such as cancer diagnosis an

Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy

A monoreactive DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) prochelator (4,7,10-tricarboxymethyl-tert-butyl ester 1,4,7,10-tetraazacyclododecane-1-acetate) was synthesised which is useful in solid-phase and solution-phase peptide synthe